TSX · BLCO.TO
Bausch + Lomb Corporation
CA$28.30-CA$0.45 (-1.57%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.81% below the high.
Loading market information…
NASDAQ · LSDI · USD
Stock price, earnings
Quote as of Jun 28, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Lucy Scientific Discovery Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.99% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lucy Scientific Discovery Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lucy Scientific Discovery Inc. focuses on the entire lifecycle of psychedelic products, from their initial research and development to their production and subsequent market release. The company's offerings include fundamental biological raw materials, unprocessed extracts, a variety of psychotropic compounds, and critical active pharmaceutical ingredients (APIs). Established in 2017, this firm, formerly known as Hollyweed North Cannabis, Inc., is headquartered in Victoria, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$28.30-CA$0.45 (-1.57%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.81% below the high.
$0.72$0.00 (0.0%)
Cyclo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.52% below the high.
$2.07+$0.10 (+5.08%)
PAVmed Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.72% below the high.
$0.39+$0.00 (+0.52%)
cbdMD, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.77% below the high.
$0.32-$0.17 (-34.28%)
InVivo Therapeutics Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 86.64% below the high.
$0.04-$0.02 (-27.27%)
Impel Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.05% below the high.
$0.03$0.00 (0.0%)
Accelerate Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.37% below the high.
$0.66-$0.21 (-24.02%)
Acorda Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.27% below the high.
